Gastric and duodenal ulcers not associated with Helicobacter pylori (in the acute phase), including ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs); functional dyspepsia chronic gastritis with increased acid-producing function of the stomach in the acute stage; gastroesophageal reflux disease (for symptoms relief) or reflux-esophagitis.
The main active ingredient: ranitidine in the form of hydrochloride.
It is produced in tablet form, in a dosage of 150 mg of ranitidine each.
The drug Ranitidin in question belongs to the group of antiulcer pharmaceutical drugs used in the treatment of erosive and ulcerative diseases of the gastrointestinal tract.
The main active ingredient is ranitidine hydrochloride. It is an antiulcer drug, is an antagonist of histamine H2 receptors. Its medicinal properties are explained by the ability to competitively inhibit the corresponding histamine receptors located in the cell membranes that create the mucous membrane of the gastric walls.
Able to reduce the secretion of hydrochloric acid in the stomach (both basal and stimulated). Effectively reduces acidity, regardless of its causes, including distension of the stomach, excessive food load, hormonal imbalance, the effect of biogenic stimulants. A decrease in the level of hydrochloric acid in the secreted gastric juices does not affect the concentration of gastrin in the blood plasma, the synthesis of gastric mucus. In addition, ranitidine has a prolonged effect.
The action of the drug begins in 2-3 hours, reaching 50% bioavailability.
This drug Ranitidin is used to treat and prevent gastrointestinal diseases such as:
- ulcer of the stomach and / or 12 duodenal ulcer, in the acute stage;
- erosive esophagitis;
- gastroesophageal reflux;
- Zollinger-Ellison syndrome.
Also used to prevent aspiration of gastric juice during / after surgery under general anesthesia.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Also, use is contraindicated in:
- oncological diseases of the stomach;
- cirrhosis of the liver;
- renal failure in severe form.
Application during pregnancy and lactation
During pregnancy and lactation, the use of this drug is contraindicated.
Method of administration and dosage
This drug Ranitidin is taken orally with water.
The recommended average dosage is 150 twice a day, or 300 mg at bedtime.
Treatment lasts 1 to 2 months.
For the prevention of exacerbations of stomach ulcers, preparations with ranitidine are taken at 150 mg at bedtime for 12 months.
In the treatment of Zollinger-Ellison syndrome, ranitidine is taken 150 mg three times a day. If urgently needed, the dose can be increased to a daily dosage of 600 or 900 mg per day.
In order to prevent the development of bleeding, an intravenous version of the drug can be used. The dosage in this case is from 50 mg to 100 mg every 6-8 hours.
In order to avoid relapses of gastric / duodenal ulcers, the drug is canceled with a gradual decrease in dosage.
The exact dosage, duration of treatment is prescribed and adjusted during the course of treatment by the attending physician, depending on the type and strength of the disease, the patient’s condition, and the body’s response to the drug.
Overdose is unlikely.
In case of an overdose, symptoms such as:
In case of an overdose, you should rinse the stomach, take enterosorbents. Hemodialysis is recommended.
When using this drug, adverse reactions may occur in the form of:
- dizziness, tiredness;
- gynecomastia, impotence, decreased libido;
- hepatitis, jaundice, pancreatitis, renal dysfunction;
- visual impairments, lowering blood pressure, bradycardia, tachycardia, arrhythmias;
- arthralgia, myalgia;
- allergic reactions in the form of rash, dermatitis, allergic myocarditis, angioedema.
Storage conditions and periods
The shelf life is 3 years.
Storage temperature – no higher than 25 ° С.